Clinical Peptides

Clinical peptides and PepMix™ Peptide Pools are increasingly needed as antigen source for clinical immune monitoring, diagnostics cell therapy and vaccine development. The diversity of applications and regulatory requirements calls for a flexible, high quality peptide partner. JPT is that partner with its outstanding know-how on peptide antigen formats, peptide specifications and formulation, peptide manufacturability manufacturability and properties as well as critical analytical release testing and batch documentation warranting smooth transition from research to clinical application.
Building on our ISO 9001:2015 certified quality management system JPT established an enhanced peptide production environment that adds critical quality measures to the standard RuO (research use only) production, which are mandatory for the clinical applications of peptides and peptide pools. Resulting quality levels termed ISO PLUS Peptides and GxP Peptides focus on the more stringent requirements of immunotherapy, cell therapy, clinical immune monitoring, clinical proteomics as well as vaccine & drug development and have been approved for a variety of clinical applications.

Quality Control for Clinical Peptides

SPECIFICATION            ISO 9001:2015
ISO 9001:2015
ISO 9001:2015
Incoming material inspection  X X X
Vendor qualification
Dedicated raw materials
Order-dedicated personell
ADCF policy
Certificate of analysis
Document management & LIM-system
Documented cleaning & calibration
Batch documentation & CoA based on IND requirements
Line clearance
X (organizational) X (spatial)
Optional: certified vials
Shipment control
Batch release
Optional: Additional QC methods
Optional: Impurity ID & qualification
Report only Report only Report only

JPT’s peptides are for research use only and not intended for human in vivo application. JPT does not warrant that any peptides and peptide pools produced under GxP or ISO PLUS conditions are applicable in clinical applications (clinical grade peptides). JPT invites its customers to visit, inspect and audit our facilities to make an educated decision on whether or not peptides or peptide pools produced under GxP or ISO PLUS conditions are suited for a specific application.

Applications for Clinical Peptides

  • Clinical immune monitoring
  • Clinical proteomics
  • Adoptive cell therapy development
  • Immunotherapy development
  • Immune diagnostic development

Application Notes:
Peptide-stimulated Expansion of Virus-specific T cells for Preventative Treatment After Allogeneic Stem Cell Transplantation
by R. Gary, M. Aigner,  A. Gerbitz, University Hospital Erlangen, Erlangen, Germany
and A. Moosmann, Helmholz Zentrum München, Munich, Germany.
Developing Multi‐HIV Antigen Specific T Cells as a Component of a Cure Strategy
by S. Lam, C.R. Cruz and C. Bollard, Children’s National Medical Center, Washington, USA
T Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant
by J. M. Keirnan, C. M. Rooney, and A. M. Leen , Baylor College of Medicine, Houston, USA

Benefits of Clinical Peptides

  • Highest peptide purities available (up to >97%)
  • Full analytical documentation (e.g. CoA, batch documention, CMC & IND support)
  • Stringent quality control beyond ISO 9001:2015 regulations
  • Vendor qualification, ADCF policy, line clearance, batch release and more
  • Broad range of analytical options (e.g. residual solvent, stability, solubility testing, endototxin, sterility testing)
  • Applicable for individual peptides, peptide libraries and peptide pools
  • Site visits & audits welcome! 

Testimonials for Clinical Peptides

"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA

"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines.  Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service.  JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations." 

Benedetto Farsaci, MD, National Cancer Institute, NIH, Bethesda, MD, USA

"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for  adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized  PepMix™Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency.”
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada

More testimonials

Clinical Peptides and Pools

Request a price
for Clinical Peptides

News Highlights

--> Read more News

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!